Rasagiline added to dopamine agonist has small benefit in Parkinson’s

From Clinical Neurology News, 25 June 2013: Rasagiline is safe and efficacious as add-on therapy in patients with early Parkinson’s disease whose symptoms are not adequately controlled with dopamine agonist monotherapy, results from a randomized, double-blind placebo-controlled study suggest. Data from the ANDANTE study showed that adding rasagiline (1 mg/day) to dopamine agonist therapy led Continue reading Rasagiline added to dopamine agonist has small benefit in Parkinson’s